<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00080119</url>
  </required_header>
  <id_info>
    <org_study_id>PACTG P1041</org_study_id>
    <secondary_id>U01AI068632</secondary_id>
    <nct_id>NCT00080119</nct_id>
  </id_info>
  <brief_title>Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled Trial to Determine the Efficacy of Isoniazid (INH) in Preventing Tuberculosis Disease and Latent Tuberculosis Infection Among Infants With Perinatal Exposure to HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Maternal Pediatric Adolescent AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Comprehensive International Program of Research on AIDS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Secure the Future Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International Maternal Pediatric Adolescent AIDS Clinical Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tuberculosis (TB) is highly endemic in sub-Saharan Africa. The increased burden of TB in
      settings with high prevalence of the Human Immunodeficiency Virus (HIV) is associated with
      high rates of transmission of Mycobacterium tuberculosis (M.tb) to both adults and children.
      Children infected with TB have a higher risk of developing severe disease than adults with
      TB. The purpose of this study was to determine if the antibiotic isoniazid (INH) prevented TB
      infection in infants born to HIV-infected mothers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tuberculosis (TB) and the Human Immunodeficiency Virus (HIV) are major public health problems
      in southern Africa, and the incidence of TB in South Africa is among the highest in the
      world. TB is caused by the highly contagious bacterium Mycobacterium tuberculosis. The use of
      Isoniazid (INH) prophylaxis in adults has been associated with reduced risk of TB disease in
      high-risk populations. Delay in initiating INH prophylaxis in children has resulted in more
      cases of childhood TB infection. This study evaluated the effectiveness of INH prophylaxis in
      preventing TB infection in infants born to HIV-infected mothers in southern Africa.

      Infants were randomly assigned to receive either INH or placebo by mouth daily, beginning
      between the 91st and 120th day of life, and at least 90 days after Bacille Calmette-Guerin
      (BCG) vaccination. At sites in South Africa, HIV-infected infants received daily
      trimethoprim/sulfamethoxazole (TMP/SMX) as Pneumocystis jiroveci pneumonia (PCP) prophylaxis
      until at least 1 year of age; HIV-uninfected infants received TMP/SMX until at least 6 months
      of age.

      The study was to follow participants for 192 weeks. Study visits occurred at study entry and
      every 12 weeks until week 192. A physical exam and blood collection occurred at each study
      visit. Infants were assessed for peripheral neuropathy every 12 weeks until week 96 and for
      TB at weeks 96, 144, and 192. The study also assessed medication adherence.

      As of November 12, 2008, follow-up was revised. All participants were permanently
      discontinued from study follow-up by February 28, 2009 and no later than May 31, 2009. Only
      clinical evaluations were performed for all participants. For HIV-infected participants, the
      study drug was stopped at the next scheduled visit. For HIV-uninfected subjects, the study
      drug was discontinued immediately.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Data Safety Monitoring Board (DSMB) recommended stopping study due to futility
  </why_stopped>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Development of Tuberculosis (TB) Disease or Death Among HIV-infected Children</measure>
    <time_frame>Through to week 96</time_frame>
    <description>Criteria for diagnosis with TB disease: Definite-isolation of Mycobacterium TB (M.tb) or +ve stain on cerebrospinal fluid (CSF); Probable- +ve acid fast bacilli (AFB) stain on fluids/tissues other than CSF and sufficient clinical criteria/radiographic evidence suggestive of TB; Possible-abnormal chest radiograph suggestive of pulmonary TB (PTB) and either a +ve tuberculin skin test (TST) or minimum score on algorithm for clinical TB. Records reviewed by Endpoint Review Group. Results report percent of participants reaching TB disease/death by week 96 calculated using the Kaplan-Meier method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time From Randomization to Development of TB Infection or Death Among Perinatally Exposed, HIV-uninfected Children</measure>
    <time_frame>Through to week 96</time_frame>
    <description>Criteria for diagnosis with TB infection were outlined in the protocol. TB infection included TB disease (see primary outcome measure 1 for definition) and latent TB infection. Latent TB infection was diagnosed by a positive tuberculin skin test (TST) based on a purified protein derivative (PPD) performed at week 96. Participant records were reviewed by an Endpoint Review Group to verify that participants had met the criteria for TB infection. Results report percent of participants reaching TB infection or death by week 96 calculated using the Kaplan-Meier method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time From Randomization to Development of TB Infection or Death Among HIV-infected Children</measure>
    <time_frame>Through to week 96</time_frame>
    <description>Criteria for diagnosis with TB infection were outlined in the protocol. TB infection included TB disease (see primary outcome measure 1 for definition) and latent TB infection. Latent TB infection was diagnosed by a positive TST based on a PPD performed at week 96. Participant records were reviewed by an Endpoint Review Group to verify that participants had met the criteria for TB infection. Results report percent of participants reaching TB infection or death by week 96 calculated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Randomization to HIV Disease Progression or Death Among HIV-infected Children</measure>
    <time_frame>Through to week 96</time_frame>
    <description>HIV disease progression was defined as any advancement in Centers for Disease Control (CDC) disease category from entry or death. If a participant was CDC disease category C at entry progression was defined as death. Results report percent of participants with HIV progression or death by week 96 calculated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Randomization to Development of TB Disease or Death Among Perinatally Exposed, HIV-uninfected Children</measure>
    <time_frame>Through to week 96</time_frame>
    <description>Criteria for diagnosis with TB disease were: Definite-isolation of M.tb or positive stain on CSF; Probable-positive AFB stain on fluids/tissues other than CSF and sufficient clinical criteria/radiographic evidence suggestive of TB; Possible-abnormal chest radiograph suggestive of PTB and either a +ve TST or minimum score on algorithm to diagnose clinical TB. All records were reviewed by an Endpoint Review Group to verify that participants had met the criteria for TB disease. Results report percent of participants reaching TB disease/death by week 96 calculated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Randomization to Development of TB Disease Among HIV Infected and Perinatally Exposed, HIV-uninfected Children</measure>
    <time_frame>Through to week 96</time_frame>
    <description>Criteria for diagnosis with TB disease were: Definite-isolation of M.tb or positive stain on CSF; Probable-positive AFB stain on fluids/tissues other than CSF and sufficient clinical criteria/radiographic evidence suggestive of TB; Possible-abnormal chest radiograph suggestive of PTB and either a +ve TST or minimum score on algorithm to diagnose clinical TB. All records were reviewed by an Endpoint Review Group to verify that participants had met the criteria for TB disease. Results report percent of participants reaching TB disease/death by week 96 calculated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Randomization to Development of TB Infection Among HIV-infected and Perinatally Exposed, HIV-uninfected Children</measure>
    <time_frame>Through to week 96</time_frame>
    <description>Criteria for diagnosis with TB infection were outlined in the protocol. TB infection included TB disease (see primary outcome measure 1 for definition) and latent TB infection. Latent TB infection was diagnosed by a positive TST based on a PPD performed at week 96. Participant records were reviewed by an Endpoint Review Group to verify that participants had met the criteria for TB infection. Results report percent of participants reaching TB infection by week 96 calculated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Randomization to Death Among HIV-infected and Perinatally Exposed, HIV-uninfected Children</measure>
    <time_frame>Through to week 96</time_frame>
    <description>Deaths from any cause were included. Results report percent of participants dying by week 96 calculated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Randomization to First New Grade 3 or Worse Adverse Event Among HIV-infected and Perinatally Exposed, HIV-uninfected Children</measure>
    <time_frame>Through to week 96</time_frame>
    <description>Signs, symptoms and laboratory values were graded according to the Division of AIDS Adverse Event Grading System. Any event of grade 3 or higher not present at entry that occurred after randomization was classified as a new event. Results report percent of participants with a new event by week 96 calculated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1354</enrollment>
  <condition>HIV Infection</condition>
  <condition>Tuberculosis</condition>
  <condition>Pneumocystis Jiroveci Pneumonia</condition>
  <arm_group>
    <arm_group_label>HIVneg/INH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Perinatally exposed, HIV-uninfected (HIVneg) children receiving Isoniazid (INH)10-20 mg/kg orally once a day for 96 weeks + Trimethoprim/Sulfamethoxazole (TMP/SMX) 5 mg/kg of TMP component orally once a day until HIV status is confirmed and child is no longer at risk of acquiring HIV through breastfeeding</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIVneg/PL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Perinatally exposed, HIV-uninfected (HIVneg) children receiving Isoniazid placebo (PL) orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until HIV status is confirmed and child is no longer at risk of acquiring HIV through breastfeeding</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIVpos/INH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected (HIVpos) children receiving Isoniazid (INH) 10-20 mg/kg orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until one year of age. TMP/SMX may have been continued after one year of age according to WHO guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIVpos/PL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>HIV-infected (HIVpos) children receiving Isoniazid placebo (PL) orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until one year of age. TMP/SMX may have been continued after one year of age according to WHO guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid (INH)</intervention_name>
    <description>Antibiotic for the prevention and treatment of TB</description>
    <arm_group_label>HIVneg/INH</arm_group_label>
    <arm_group_label>HIVpos/INH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethoprim/Sulfamethoxazole (TMP/SMX)</intervention_name>
    <description>Antibiotic for the prevention and treatment of pneumocystis pneumonia (PCP)</description>
    <arm_group_label>HIVneg/INH</arm_group_label>
    <arm_group_label>HIVpos/INH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid Placebo (PL)</intervention_name>
    <description>Isoniazid placebo and TMP/SMX</description>
    <arm_group_label>HIVneg/PL</arm_group_label>
    <arm_group_label>HIVpos/PL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mother is HIV-infected. Hard copy documentation of the mother's HIV infection is
             unnecessary if a positive DNA PCR from her infant is available.

          -  Received Bacille Calmette-Guerin (BCG) vaccine up to and including the 30th day of
             life and at least 90 days prior to study entry

          -  Able to complete all study requirements

          -  Physician assessment of age-appropriate neurodevelopment in which the chronological
             age is corrected for gestational age for prematurely born infants

          -  Parent or legal guardian able and willing to provide signed informed consent

          -  Plan to live in the study area for at least 4 years

          -  For inclusion in HIV-infected stratum, infant must have a positive HIV-1 DNA PCR; for
             inclusion in HIV-uninfected stratum, infant must have a negative HIV-1 DNA PCR
             performed at &gt;= 4 weeks of age

        Exclusion Criteria:

          -  Previous diagnosis of TB infection, TB disease or current treatment for TB infection
             or TB disease

          -  Previous receipt of INH

          -  Contact with a known acid fast bacilli (AFB) sputum smear or culture-positive case of
             TB before study entry

          -  Current acute or recurrent (3 or more prior episodes) lower respiratory tract disease

          -  Chronic persistent diarrhea

          -  Failure to thrive

          -  Contraindications for use of INH or TMP/SMX

          -  Require certain medications

          -  Known or suspected immune system diseases other than HIV

          -  Current or previous diagnosis of or treatment for cancer

          -  Current immunosuppressive therapy greater than 1 mg/kg/day of prednisone or equivalent

          -  Anticipated long-term oral or intravenous corticosteroid therapy (greater than 3
             weeks). Those receiving nonsteroidal anti-inflammatory agents and inhaled
             corticosteroids are not excluded.

          -  Grade 3 or greater AST/SGOT, ALT/SGPT, ANC, hemoglobin, platelet count, rash,
             neuropathy, or myopathy at screening

          -  Any Grade 4 clinical or laboratory toxicity within 14 days prior to study entry

          -  Other acute or chronic conditions that, in the opinion of the investigator, may
             interfere with the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>91 Days</minimum_age>
    <maximum_age>120 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shabir Madhi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Witwatersrand, South Africa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George McSherry, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UMDNJ - New Jersey Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles D. Mitchell, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Princess Marina Hospital</name>
      <address>
        <city>Gaborone</city>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cape Town, Red Cross Children's Hospital</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Stellenbosch, Tygerberg Hospital</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nelson R. Mandela School of Medicine, University of KwaZulu Natal, Durban</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perinatal HIV Research Unit at Chris Hani Baragwanath Hospital</name>
      <address>
        <city>Johannesburg</city>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chris Hani Baragwanath Hospital, Harriet Shezi Clinic</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Botswana</country>
    <country>South Africa</country>
  </location_countries>
  <reference>
    <citation>Chintu C, Mwaba P. Tuberculosis in children with human immunodeficiency virus infection. Int J Tuberc Lung Dis. 2005 May;9(5):477-84. Review.</citation>
    <PMID>15875917</PMID>
  </reference>
  <reference>
    <citation>Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003 May 12;163(9):1009-21. Review.</citation>
    <PMID>12742798</PMID>
  </reference>
  <reference>
    <citation>de Jong BC, Israelski DM, Corbett EL, Small PM. Clinical management of tuberculosis in the context of HIV infection. Annu Rev Med. 2004;55:283-301. Review.</citation>
    <PMID>14746522</PMID>
  </reference>
  <reference>
    <citation>Toossi Z. Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease. J Infect Dis. 2003 Oct 15;188(8):1146-55. Epub 2003 Sep 30. Review.</citation>
    <PMID>14551885</PMID>
  </reference>
  <results_reference>
    <citation>Cotton MF, Schaaf HS, Lottering G, Weber HL, Coetzee J, Nachman S; PACTG 1041 Team. Tuberculosis exposure in HIV-exposed infants in a high-prevalence setting. Int J Tuberc Lung Dis. 2008 Feb;12(2):225-7.</citation>
    <PMID>18230259</PMID>
  </results_reference>
  <results_reference>
    <citation>Cotton M, Kim S, Rabie H, Coetzee J, Nachman S. A window into a public program for prevention of mother to child transmission of HIV: evidence from a prospective clinical trial. South Afr J HIV Med. 2009 Jan 1;10(4):16-19.</citation>
    <PMID>20607114</PMID>
  </results_reference>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2004</study_first_submitted>
  <study_first_submitted_qc>March 24, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2004</study_first_posted>
  <results_first_submitted>July 1, 2010</results_first_submitted>
  <results_first_submitted_qc>October 1, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 19, 2010</results_first_posted>
  <last_update_submitted>February 10, 2011</last_update_submitted>
  <last_update_submitted_qc>February 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Wende Levy</name_title>
    <organization>IMPAACT</organization>
  </responsible_party>
  <keyword>Treatment Naive</keyword>
  <keyword>INH Prophylaxis</keyword>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Pneumonia, Pneumocystis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were recruited at four study sites, three in South Africa and one in Botswana, between December 13, 2004 and June 26, 2008</recruitment_details>
      <pre_assignment_details>Infants perinatally exposed to HIV 91-120 days with documented receipt of Bacille Calmette-Guerin (BCG) vaccine by 30 days (&gt;=90 days since receipt), no previous diagnosis or treatment of TB or contact with known TB case, stratified by HIV and randomized to receive blinded INH or INH placebo. 3 participants randomized but did not start treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>HIVneg/INH</title>
          <description>Perinatally exposed, HIV-uninfected (HIVneg) children receiving Isoniazid (INH)10-20 mg/kg orally once a day for 96 weeks + Trimethoprim/Sulfamethoxazole (TMP/SMX) 5 mg/kg of TMP component orally once a day until HIV status is confirmed and child is no longer at risk of acquiring HIV through breastfeeding</description>
        </group>
        <group group_id="P2">
          <title>HIVneg/PL</title>
          <description>Perinatally-exposed, HIV-uninfected (HIVneg) children receiving Isoniazid placebo (PL) orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until HIV status is confirmed and child is no longer at risk of acquiring HIV through breastfeeding</description>
        </group>
        <group group_id="P3">
          <title>HIVpos/INH</title>
          <description>HIV-infected (HIVpos) children receiving Isoniazid (INH) 10-20 mg/kg orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until one year of age. TMP/SMX may have been continued after one year of age according to WHO guidelines.</description>
        </group>
        <group group_id="P4">
          <title>HIVpos/PL</title>
          <description>HIV-infected (HIVpos) children receiving Isoniazid placebo (PL) orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until one year of age. TMP/SMX may have been continued after one year of age according to WHO guidelines.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="403"/>
                <participants group_id="P2" count="401"/>
                <participants group_id="P3" count="273"/>
                <participants group_id="P4" count="274"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="347"/>
                <participants group_id="P2" count="339"/>
                <participants group_id="P3" count="108"/>
                <participants group_id="P4" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="62"/>
                <participants group_id="P3" count="165"/>
                <participants group_id="P4" count="163"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Discontinued because of study closure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="130"/>
                <participants group_id="P4" count="141"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to get to clinic</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unwilling to adhere to study requirement</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HIVneg/INH</title>
          <description>Perinatally exposed, HIV-uninfected (HIVneg) children receiving Isoniazid (INH)10-20 mg/kg orally once a day for 96 weeks + Trimethoprim/Sulfamethoxazole (TMP/SMX) 5 mg/kg of TMP component orally once a day until HIV status is confirmed and child is no longer at risk of acquiring HIV through breastfeeding</description>
        </group>
        <group group_id="B2">
          <title>HIVneg/PL</title>
          <description>Perinatally-exposed, HIV-uninfected (HIVneg) children receiving Isoniazid placebo (PL) orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until HIV status is confirmed and child is no longer at risk of acquiring HIV through breastfeeding</description>
        </group>
        <group group_id="B3">
          <title>HIVpos/INH</title>
          <description>HIV-infected (HIVpos) children receiving Isoniazid (INH) 10-20 mg/kg orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until one year of age. TMP/SMX may have been continued after one year of age according to WHO guidelines.</description>
        </group>
        <group group_id="B4">
          <title>HIVpos/PL</title>
          <description>HIV-infected (HIVpos) children receiving Isoniazid placebo (PL) orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until one year of age. TMP/SMX may have been continued after one year of age according to WHO guidelines.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="403"/>
            <count group_id="B2" value="401"/>
            <count group_id="B3" value="273"/>
            <count group_id="B4" value="274"/>
            <count group_id="B5" value="1351"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>91-100 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="258"/>
                    <measurement group_id="B2" value="253"/>
                    <measurement group_id="B3" value="171"/>
                    <measurement group_id="B4" value="192"/>
                    <measurement group_id="B5" value="874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>101-110 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>111-120 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                    <measurement group_id="B2" value="190"/>
                    <measurement group_id="B3" value="159"/>
                    <measurement group_id="B4" value="151"/>
                    <measurement group_id="B5" value="703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                    <measurement group_id="B2" value="211"/>
                    <measurement group_id="B3" value="114"/>
                    <measurement group_id="B4" value="123"/>
                    <measurement group_id="B5" value="648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Indigenous African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="389"/>
                    <measurement group_id="B2" value="386"/>
                    <measurement group_id="B3" value="264"/>
                    <measurement group_id="B4" value="272"/>
                    <measurement group_id="B5" value="1311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed ancestry/other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at receipt of Bacille Calmette-Guerin (BCG) vaccination (days)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;= 7 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="395"/>
                    <measurement group_id="B2" value="392"/>
                    <measurement group_id="B3" value="255"/>
                    <measurement group_id="B4" value="258"/>
                    <measurement group_id="B5" value="1300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8-29 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Any smoker in household</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="191"/>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="131"/>
                    <measurement group_id="B5" value="619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                    <measurement group_id="B2" value="224"/>
                    <measurement group_id="B3" value="153"/>
                    <measurement group_id="B4" value="141"/>
                    <measurement group_id="B5" value="729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Birth weight (grams)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;2500 grams</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="56"/>
                    <measurement group_id="B5" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 2500 grams</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="354"/>
                    <measurement group_id="B2" value="352"/>
                    <measurement group_id="B3" value="205"/>
                    <measurement group_id="B4" value="218"/>
                    <measurement group_id="B5" value="1129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4%</title>
          <description>Only for HIV-infected participants. Those in the HIV-infected stratum that were later determined to be HIV-uninfected are recorded as not applicable.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;20%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20%-&lt;25%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 25%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="162"/>
                    <measurement group_id="B4" value="157"/>
                    <measurement group_id="B5" value="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not applicable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="403"/>
                    <measurement group_id="B2" value="401"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Centers for Disease Control (CDC) Disease Category</title>
          <description>Only for HIV-infected participants.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Category N or A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="252"/>
                    <measurement group_id="B4" value="244"/>
                    <measurement group_id="B5" value="496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIV-uninfected on repeat test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not applicable (HIV-uninfected)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="403"/>
                    <measurement group_id="B2" value="401"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="804"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Caregiver currently smokes</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="392"/>
                    <measurement group_id="B2" value="376"/>
                    <measurement group_id="B3" value="257"/>
                    <measurement group_id="B4" value="264"/>
                    <measurement group_id="B5" value="1289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ever breastfed</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="379"/>
                    <measurement group_id="B2" value="377"/>
                    <measurement group_id="B3" value="236"/>
                    <measurement group_id="B4" value="238"/>
                    <measurement group_id="B5" value="1230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV-1 RNA (copies/ml)</title>
          <description>Only for HIV-infected participants. Those in the HIV-infected stratum that were later determined to be HIV-uninfected are recorded as not applicable.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;= 400 copies/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>401 - &lt;20,000 copies/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20,000 - &lt; 750,000 copies/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="86"/>
                    <measurement group_id="B5" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 750,000 copies/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="129"/>
                    <measurement group_id="B4" value="116"/>
                    <measurement group_id="B5" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not applicable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="403"/>
                    <measurement group_id="B2" value="401"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of tuberculosis (TB) in mother</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="370"/>
                    <measurement group_id="B2" value="376"/>
                    <measurement group_id="B3" value="259"/>
                    <measurement group_id="B4" value="249"/>
                    <measurement group_id="B5" value="1254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Housing</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Formal (brick) house</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="235"/>
                    <measurement group_id="B2" value="233"/>
                    <measurement group_id="B3" value="162"/>
                    <measurement group_id="B4" value="183"/>
                    <measurement group_id="B5" value="813"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Informal (shack/wooden)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="109"/>
                    <measurement group_id="B4" value="89"/>
                    <measurement group_id="B5" value="534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hostel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>On antiretrovirals at entry</title>
          <description>Only for HIV-infected participants. Those in the HIV-infected stratum that were later determined to be HIV-uninfected are recorded as not applicable.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="93"/>
                    <measurement group_id="B5" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="194"/>
                    <measurement group_id="B4" value="178"/>
                    <measurement group_id="B5" value="372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not applicable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="403"/>
                    <measurement group_id="B2" value="401"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Site of enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Johannesburg, S Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="259"/>
                    <measurement group_id="B2" value="260"/>
                    <measurement group_id="B3" value="180"/>
                    <measurement group_id="B4" value="179"/>
                    <measurement group_id="B5" value="878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cape Town, S Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Durban, S Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gaborone, Botswana</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Development of Tuberculosis (TB) Disease or Death Among HIV-infected Children</title>
        <description>Criteria for diagnosis with TB disease: Definite-isolation of Mycobacterium TB (M.tb) or +ve stain on cerebrospinal fluid (CSF); Probable- +ve acid fast bacilli (AFB) stain on fluids/tissues other than CSF and sufficient clinical criteria/radiographic evidence suggestive of TB; Possible-abnormal chest radiograph suggestive of pulmonary TB (PTB) and either a +ve tuberculin skin test (TST) or minimum score on algorithm for clinical TB. Records reviewed by Endpoint Review Group. Results report percent of participants reaching TB disease/death by week 96 calculated using the Kaplan-Meier method.</description>
        <time_frame>Through to week 96</time_frame>
        <population>Includes HIVpos who started study treatment. Time from randomization to TB disease/death was calculated. Participants lost-to-follow-up (LTF) &lt;96 wks (+12wks) censored at the time of LTF. Participants in follow-up at 96 wks free of TB disease censored at 96 wks. Participants on study when study discontinued censored at discontinuation visit.</population>
        <group_list>
          <group group_id="O1">
            <title>HIVpos/INH</title>
          </group>
          <group group_id="O2">
            <title>HIVpos/PL</title>
          </group>
        </group_list>
        <measure>
          <title>Time to Development of Tuberculosis (TB) Disease or Death Among HIV-infected Children</title>
          <description>Criteria for diagnosis with TB disease: Definite-isolation of Mycobacterium TB (M.tb) or +ve stain on cerebrospinal fluid (CSF); Probable- +ve acid fast bacilli (AFB) stain on fluids/tissues other than CSF and sufficient clinical criteria/radiographic evidence suggestive of TB; Possible-abnormal chest radiograph suggestive of pulmonary TB (PTB) and either a +ve tuberculin skin test (TST) or minimum score on algorithm for clinical TB. Records reviewed by Endpoint Review Group. Results report percent of participants reaching TB disease/death by week 96 calculated using the Kaplan-Meier method.</description>
          <population>Includes HIVpos who started study treatment. Time from randomization to TB disease/death was calculated. Participants lost-to-follow-up (LTF) &lt;96 wks (+12wks) censored at the time of LTF. Participants in follow-up at 96 wks free of TB disease censored at 96 wks. Participants on study when study discontinued censored at discontinuation visit.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4"/>
                    <measurement group_id="O2" value="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.93</p_value>
            <p_value_desc>Threshold p-value for significance = 0.0492</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
            <estimate_desc>Hazard ratio for INH relative to Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time From Randomization to Development of TB Infection or Death Among Perinatally Exposed, HIV-uninfected Children</title>
        <description>Criteria for diagnosis with TB infection were outlined in the protocol. TB infection included TB disease (see primary outcome measure 1 for definition) and latent TB infection. Latent TB infection was diagnosed by a positive tuberculin skin test (TST) based on a purified protein derivative (PPD) performed at week 96. Participant records were reviewed by an Endpoint Review Group to verify that participants had met the criteria for TB infection. Results report percent of participants reaching TB infection or death by week 96 calculated using the Kaplan-Meier method.</description>
        <time_frame>Through to week 96</time_frame>
        <population>HIVneg who started study treatment were included. Time from randomization to first of TB infection/death was calculated. Participants lost-to-follow-up before 96 wks were censored at the time of loss-to-follow-up. Participants in follow-up at 96 weeks (+12 week window) who were free of TB infection were censored at 96 weeks (+12 week window).</population>
        <group_list>
          <group group_id="O1">
            <title>HIVneg/INH</title>
          </group>
          <group group_id="O2">
            <title>HIVneg/PL</title>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to Development of TB Infection or Death Among Perinatally Exposed, HIV-uninfected Children</title>
          <description>Criteria for diagnosis with TB infection were outlined in the protocol. TB infection included TB disease (see primary outcome measure 1 for definition) and latent TB infection. Latent TB infection was diagnosed by a positive tuberculin skin test (TST) based on a purified protein derivative (PPD) performed at week 96. Participant records were reviewed by an Endpoint Review Group to verify that participants had met the criteria for TB infection. Results report percent of participants reaching TB infection or death by week 96 calculated using the Kaplan-Meier method.</description>
          <population>HIVneg who started study treatment were included. Time from randomization to first of TB infection/death was calculated. Participants lost-to-follow-up before 96 wks were censored at the time of loss-to-follow-up. Participants in follow-up at 96 weeks (+12 week window) who were free of TB infection were censored at 96 weeks (+12 week window).</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="401"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9"/>
                    <measurement group_id="O2" value="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.43</p_value>
            <p_value_desc>Threshold p-value for significance = 0.0493</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
            <estimate_desc>Hazard ratio for INH relative to Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Randomization to Development of TB Infection or Death Among HIV-infected Children</title>
        <description>Criteria for diagnosis with TB infection were outlined in the protocol. TB infection included TB disease (see primary outcome measure 1 for definition) and latent TB infection. Latent TB infection was diagnosed by a positive TST based on a PPD performed at week 96. Participant records were reviewed by an Endpoint Review Group to verify that participants had met the criteria for TB infection. Results report percent of participants reaching TB infection or death by week 96 calculated using the Kaplan-Meier method.</description>
        <time_frame>Through to week 96</time_frame>
        <population>HIVpos starting study treatment were included. Time from randomization to first of TB infection/death was calculated. Participants LTF &lt;96 weeks (+12 wk) censored at the time LTF. Participants in follow-up at 96 wks free of TB infection censored at 96 wks. Participants on study when study discontinued were censored at discontinuation visit.</population>
        <group_list>
          <group group_id="O1">
            <title>HIVpos/INH</title>
          </group>
          <group group_id="O2">
            <title>HIVpos/PL</title>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to Development of TB Infection or Death Among HIV-infected Children</title>
          <description>Criteria for diagnosis with TB infection were outlined in the protocol. TB infection included TB disease (see primary outcome measure 1 for definition) and latent TB infection. Latent TB infection was diagnosed by a positive TST based on a PPD performed at week 96. Participant records were reviewed by an Endpoint Review Group to verify that participants had met the criteria for TB infection. Results report percent of participants reaching TB infection or death by week 96 calculated using the Kaplan-Meier method.</description>
          <population>HIVpos starting study treatment were included. Time from randomization to first of TB infection/death was calculated. Participants LTF &lt;96 weeks (+12 wk) censored at the time LTF. Participants in follow-up at 96 wks free of TB infection censored at 96 wks. Participants on study when study discontinued were censored at discontinuation visit.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4"/>
                    <measurement group_id="O2" value="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Randomization to HIV Disease Progression or Death Among HIV-infected Children</title>
        <description>HIV disease progression was defined as any advancement in Centers for Disease Control (CDC) disease category from entry or death. If a participant was CDC disease category C at entry progression was defined as death. Results report percent of participants with HIV progression or death by week 96 calculated using the Kaplan-Meier method.</description>
        <time_frame>Through to week 96</time_frame>
        <population>Includes HIVpos starting study treatment. Time from randomization to first of disease progression/death calculated. Censored if LTF &lt;96 wks, at 96 wks (if on study) or at discontinuation visit. Participants found to be HIVneg upon repeat testing could only progress by meeting a death endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>HIVpos/INH</title>
          </group>
          <group group_id="O2">
            <title>HIVpos/PL</title>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to HIV Disease Progression or Death Among HIV-infected Children</title>
          <description>HIV disease progression was defined as any advancement in Centers for Disease Control (CDC) disease category from entry or death. If a participant was CDC disease category C at entry progression was defined as death. Results report percent of participants with HIV progression or death by week 96 calculated using the Kaplan-Meier method.</description>
          <population>Includes HIVpos starting study treatment. Time from randomization to first of disease progression/death calculated. Censored if LTF &lt;96 wks, at 96 wks (if on study) or at discontinuation visit. Participants found to be HIVneg upon repeat testing could only progress by meeting a death endpoint.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.6"/>
                    <measurement group_id="O2" value="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Randomization to Development of TB Disease or Death Among Perinatally Exposed, HIV-uninfected Children</title>
        <description>Criteria for diagnosis with TB disease were: Definite-isolation of M.tb or positive stain on CSF; Probable-positive AFB stain on fluids/tissues other than CSF and sufficient clinical criteria/radiographic evidence suggestive of TB; Possible-abnormal chest radiograph suggestive of PTB and either a +ve TST or minimum score on algorithm to diagnose clinical TB. All records were reviewed by an Endpoint Review Group to verify that participants had met the criteria for TB disease. Results report percent of participants reaching TB disease/death by week 96 calculated using the Kaplan-Meier method.</description>
        <time_frame>Through to week 96</time_frame>
        <population>Includes HIVneg who started study treatment. Time from randomization to the first of TB disease/death was calculated. Participants lost-to-follow-up before 96 weeks (+12 week window)were censored at the time of loss-to-follow-up. Participants in follow-up at 96 weeks who were free of TB disease were censored at 96 weeks (+12 week window).</population>
        <group_list>
          <group group_id="O1">
            <title>HIVneg/INH</title>
          </group>
          <group group_id="O2">
            <title>HIVneg/PL</title>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to Development of TB Disease or Death Among Perinatally Exposed, HIV-uninfected Children</title>
          <description>Criteria for diagnosis with TB disease were: Definite-isolation of M.tb or positive stain on CSF; Probable-positive AFB stain on fluids/tissues other than CSF and sufficient clinical criteria/radiographic evidence suggestive of TB; Possible-abnormal chest radiograph suggestive of PTB and either a +ve TST or minimum score on algorithm to diagnose clinical TB. All records were reviewed by an Endpoint Review Group to verify that participants had met the criteria for TB disease. Results report percent of participants reaching TB disease/death by week 96 calculated using the Kaplan-Meier method.</description>
          <population>Includes HIVneg who started study treatment. Time from randomization to the first of TB disease/death was calculated. Participants lost-to-follow-up before 96 weeks (+12 week window)were censored at the time of loss-to-follow-up. Participants in follow-up at 96 weeks who were free of TB disease were censored at 96 weeks (+12 week window).</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="401"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Randomization to Development of TB Disease Among HIV Infected and Perinatally Exposed, HIV-uninfected Children</title>
        <description>Criteria for diagnosis with TB disease were: Definite-isolation of M.tb or positive stain on CSF; Probable-positive AFB stain on fluids/tissues other than CSF and sufficient clinical criteria/radiographic evidence suggestive of TB; Possible-abnormal chest radiograph suggestive of PTB and either a +ve TST or minimum score on algorithm to diagnose clinical TB. All records were reviewed by an Endpoint Review Group to verify that participants had met the criteria for TB disease. Results report percent of participants reaching TB disease/death by week 96 calculated using the Kaplan-Meier method.</description>
        <time_frame>Through to week 96</time_frame>
        <population>Includes all starting study treatment. Time from randomization to development of TB disease was calculated. Participants LTF &lt;96 wks (+12 wks) censored at time of LTF. Participants in follow-up at 96 wks free of TB disease censored at 96 wks. HIVpos on study when study discontinued were censored at their discontinuation visit.</population>
        <group_list>
          <group group_id="O1">
            <title>HIVneg/INH</title>
          </group>
          <group group_id="O2">
            <title>HIVneg/PL</title>
          </group>
          <group group_id="O3">
            <title>HIVpos/INH</title>
          </group>
          <group group_id="O4">
            <title>HIVpos/PL</title>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to Development of TB Disease Among HIV Infected and Perinatally Exposed, HIV-uninfected Children</title>
          <description>Criteria for diagnosis with TB disease were: Definite-isolation of M.tb or positive stain on CSF; Probable-positive AFB stain on fluids/tissues other than CSF and sufficient clinical criteria/radiographic evidence suggestive of TB; Possible-abnormal chest radiograph suggestive of PTB and either a +ve TST or minimum score on algorithm to diagnose clinical TB. All records were reviewed by an Endpoint Review Group to verify that participants had met the criteria for TB disease. Results report percent of participants reaching TB disease/death by week 96 calculated using the Kaplan-Meier method.</description>
          <population>Includes all starting study treatment. Time from randomization to development of TB disease was calculated. Participants LTF &lt;96 wks (+12 wks) censored at time of LTF. Participants in follow-up at 96 wks free of TB disease censored at 96 wks. HIVpos on study when study discontinued were censored at their discontinuation visit.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="401"/>
                <count group_id="O3" value="273"/>
                <count group_id="O4" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8"/>
                    <measurement group_id="O2" value="8.5"/>
                    <measurement group_id="O3" value="20.3"/>
                    <measurement group_id="O4" value="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Randomization to Development of TB Infection Among HIV-infected and Perinatally Exposed, HIV-uninfected Children</title>
        <description>Criteria for diagnosis with TB infection were outlined in the protocol. TB infection included TB disease (see primary outcome measure 1 for definition) and latent TB infection. Latent TB infection was diagnosed by a positive TST based on a PPD performed at week 96. Participant records were reviewed by an Endpoint Review Group to verify that participants had met the criteria for TB infection. Results report percent of participants reaching TB infection by week 96 calculated using the Kaplan-Meier method.</description>
        <time_frame>Through to week 96</time_frame>
        <population>Includes all starting study treatment. Time from randomization to development of TB infection was calculated. Participants LTF &lt;96 weeks (+12 wks) censored at the time of LTF. Participants in follow-up at 96 wks free of TB infection were censored at 96 wks. HIVpos on study when study discontinued censored at their discontinuation visit.</population>
        <group_list>
          <group group_id="O1">
            <title>HIVneg/INH</title>
          </group>
          <group group_id="O2">
            <title>HIVneg/PL</title>
          </group>
          <group group_id="O3">
            <title>HIVpos/INH</title>
          </group>
          <group group_id="O4">
            <title>HIVpos/PL</title>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to Development of TB Infection Among HIV-infected and Perinatally Exposed, HIV-uninfected Children</title>
          <description>Criteria for diagnosis with TB infection were outlined in the protocol. TB infection included TB disease (see primary outcome measure 1 for definition) and latent TB infection. Latent TB infection was diagnosed by a positive TST based on a PPD performed at week 96. Participant records were reviewed by an Endpoint Review Group to verify that participants had met the criteria for TB infection. Results report percent of participants reaching TB infection by week 96 calculated using the Kaplan-Meier method.</description>
          <population>Includes all starting study treatment. Time from randomization to development of TB infection was calculated. Participants LTF &lt;96 weeks (+12 wks) censored at the time of LTF. Participants in follow-up at 96 wks free of TB infection were censored at 96 wks. HIVpos on study when study discontinued censored at their discontinuation visit.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="401"/>
                <count group_id="O3" value="273"/>
                <count group_id="O4" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4"/>
                    <measurement group_id="O2" value="12.1"/>
                    <measurement group_id="O3" value="22.4"/>
                    <measurement group_id="O4" value="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Randomization to Death Among HIV-infected and Perinatally Exposed, HIV-uninfected Children</title>
        <description>Deaths from any cause were included. Results report percent of participants dying by week 96 calculated using the Kaplan-Meier method.</description>
        <time_frame>Through to week 96</time_frame>
        <population>Includes all starting study treatment. Time from randomization to death was calculated. Participants LTF &lt;96 weeks (+12 wks) censored at the time of LTF. Participants in follow-up at 96 wks (+12 wks) censored at 96 weeks. HIVpos on study when study was discontinued were censored at their discontinuation visit.</population>
        <group_list>
          <group group_id="O1">
            <title>HIVneg/INH</title>
          </group>
          <group group_id="O2">
            <title>HIVneg/PL</title>
          </group>
          <group group_id="O3">
            <title>HIVpos/INH</title>
          </group>
          <group group_id="O4">
            <title>HIVpos/PL</title>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to Death Among HIV-infected and Perinatally Exposed, HIV-uninfected Children</title>
          <description>Deaths from any cause were included. Results report percent of participants dying by week 96 calculated using the Kaplan-Meier method.</description>
          <population>Includes all starting study treatment. Time from randomization to death was calculated. Participants LTF &lt;96 weeks (+12 wks) censored at the time of LTF. Participants in follow-up at 96 wks (+12 wks) censored at 96 weeks. HIVpos on study when study was discontinued were censored at their discontinuation visit.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="401"/>
                <count group_id="O3" value="273"/>
                <count group_id="O4" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.8"/>
                    <measurement group_id="O3" value="11.6"/>
                    <measurement group_id="O4" value="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Randomization to First New Grade 3 or Worse Adverse Event Among HIV-infected and Perinatally Exposed, HIV-uninfected Children</title>
        <description>Signs, symptoms and laboratory values were graded according to the Division of AIDS Adverse Event Grading System. Any event of grade 3 or higher not present at entry that occurred after randomization was classified as a new event. Results report percent of participants with a new event by week 96 calculated using the Kaplan-Meier method.</description>
        <time_frame>Through to week 96</time_frame>
        <population>Includes all starting treatment. Time from randomization to first new adverse event (AE) calculated. For lab toxicities, censored at visit following permanent discontinuation of study drugs. For signs/symptoms, participants in follow-up at 96 wks (+12) with no new grade &gt;=3 AE censored at 96 wks. Participants LTF &lt;96 wks censored at LTF.</population>
        <group_list>
          <group group_id="O1">
            <title>HIVneg/INH</title>
          </group>
          <group group_id="O2">
            <title>HIVneg/PL</title>
          </group>
          <group group_id="O3">
            <title>HIVpos/INH</title>
          </group>
          <group group_id="O4">
            <title>HIVpos/PL</title>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to First New Grade 3 or Worse Adverse Event Among HIV-infected and Perinatally Exposed, HIV-uninfected Children</title>
          <description>Signs, symptoms and laboratory values were graded according to the Division of AIDS Adverse Event Grading System. Any event of grade 3 or higher not present at entry that occurred after randomization was classified as a new event. Results report percent of participants with a new event by week 96 calculated using the Kaplan-Meier method.</description>
          <population>Includes all starting treatment. Time from randomization to first new adverse event (AE) calculated. For lab toxicities, censored at visit following permanent discontinuation of study drugs. For signs/symptoms, participants in follow-up at 96 wks (+12) with no new grade &gt;=3 AE censored at 96 wks. Participants LTF &lt;96 wks censored at LTF.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="401"/>
                <count group_id="O3" value="273"/>
                <count group_id="O4" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>New &gt;=grade 3 sign/symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="4.2"/>
                    <measurement group_id="O3" value="16.8"/>
                    <measurement group_id="O4" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New &gt;= grade 3 peripheral neuropathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="0.3"/>
                    <measurement group_id="O3" value="2.4"/>
                    <measurement group_id="O4" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New &gt;=grade 3 lab abnormality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="4.6"/>
                    <measurement group_id="O3" value="11.3"/>
                    <measurement group_id="O4" value="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New &gt;=grade 3 hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.8"/>
                    <measurement group_id="O4" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New &gt;=grade 3 ANC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="0.3"/>
                    <measurement group_id="O3" value="1.6"/>
                    <measurement group_id="O4" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New &gt;=grade 3 platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.7"/>
                    <measurement group_id="O4" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New &gt;=grade 3 SGOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="2.8"/>
                    <measurement group_id="O3" value="0.4"/>
                    <measurement group_id="O4" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New &gt;=grade 3 SGPT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                    <measurement group_id="O2" value="4.4"/>
                    <measurement group_id="O3" value="5.9"/>
                    <measurement group_id="O4" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From study enrollment until study completion and before May 25, 2009 (primary completion date)</time_frame>
      <desc>Expedited adverse event (AE) reporting followed Intensive Division of AIDS (DAIDS) Reporting Level, which included AEs resulting in death, congenital anomalies, fetal losses, significant disabilities, requiring hospitalization, and &gt;=grade 3 AEs defined by the &quot;DAIDS Table for Grading the Severity of Adult and Pediatric AEs&quot;, V1.0, 12/2004.</desc>
      <group_list>
        <group group_id="E1">
          <title>HIVneg/INH</title>
          <description>Perinatally exposed, HIV-uninfected (HIVneg) children receiving Isoniazid (INH)10-20 mg/kg orally once a day for 96 weeks + Trimethoprim/Sulfamethoxazole (TMP/SMX) 5 mg/kg of TMP component orally once a day until HIV status is confirmed and child is no longer at risk of acquiring HIV through breastfeeding</description>
        </group>
        <group group_id="E2">
          <title>HIVneg/PL</title>
          <description>Perinatally-exposed, HIV-uninfected (HIVneg) children receiving Isoniazid placebo (PL) orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until HIV status is confirmed and child is no longer at risk of acquiring HIV through breastfeeding</description>
        </group>
        <group group_id="E3">
          <title>HIVpos/INH</title>
          <description>HIV-infected (HIVpos) children receiving Isoniazid (INH) 10-20 mg/kg orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until one year of age. TMP/SMX may have been continued after one year of age according to WHO guidelines.</description>
        </group>
        <group group_id="E4">
          <title>HIVpos/PL</title>
          <description>HIV-infected (HIVpos) children receiving Isoniazid placebo (PL) orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until one year of age. TMP/SMX may have been continued after one year of age according to WHO guidelines.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Accidental death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Sudden infant death syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Encephalitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>HIV infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pneumonia cytomegaloviral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pneumonia herpes viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pneumonia necrotising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Tuberculosis of eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="353" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="368" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="264" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="268" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>AIDS encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="79" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="140" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="162" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="63" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Tonsilitis</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="130" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="114" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="109" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="86" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="176" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="176" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="100" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="105" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="87" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="401"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="273"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In accordance with the Clinical Trial Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>DSMB recommended stopping study due to futility: &quot;no compelling reason to enroll additional infants&quot; or &quot;to continue to treat participants with the blinded study medication&quot;. Week 192 analyses not done as &lt;4% (26%) of HIVpos (HIVneg) reached wk 192</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinicaltrials.gov Coordinator</name_or_title>
      <organization>Center for Biostatistics in AIDS Research, Harvard School of Public Health</organization>
      <phone>(617) 432-2829</phone>
      <email>CBAR.ClinicalTrials.Gov@sdac.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

